Adverum Biotechnologies, Inc.
NASDAQ:ADVM
8 (USD) • At close November 8, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Adverum Biotechnologies, Inc. |
Symbool | ADVM |
Munteenheid | USD |
Prijs | 8 |
Beurswaarde | 166,407,200 |
Dividendpercentage | 0% |
52-weken bereik | 6.38 - 29.7 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Laurent Fischer |
Website | https://www.adverum.com |
An error occurred while fetching data.
Over Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)